As of September 30, 2026, Xilio Therapeutics, Inc. carries a market capitalization of 59.62M, placing it among publicly traded companies globally. Its enterprise value stands at -56.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 59.62M |
| Enterprise Value | -56.60M |
Xilio Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 3, 2027.
| Earnings Date | 3/3/2027 |
As of September 30, 2026, Xilio Therapeutics, Inc. has 6.59M shares outstanding.
| Shares Outstanding | 6.59M |
These figures are as of September 30, 2026. The price-to-sales ratio is 2.29, and the price-to-book ratio stands at 0.87.
| PS Ratio | 2.29 |
| PB Ratio | 0.87 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | -2.27 |
| P/OCF Ratio | -2.22 |
As of September 30, 2026, Xilio Therapeutics, Inc. maintains a current ratio of 4.72, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.72 |
| Quick Ratio | 4.56 |
| Debt / Equity | 8.73 |
| Debt / EBITDA | -0.15 |
These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -8.56, reflecting losses generated across the asset base. The company generates approximately 723,815.79 in revenue per employee across its workforce of 76.00, a quick read on workforce productivity versus industry peers.
| Return on Assets (ROA) | -8.56 |
| Revenue Per Employee | 723,815.79 |
| Employee Count | 76.00 |
As of the close on November 16, 2026, Xilio Therapeutics, Inc.'s stock has declined approximately 22.23% over the past 52 weeks. The 50-day moving average sits at 8.67, while the 200-day moving average is 8.48.
| 52-Week Price Change | -22.23% |
| 50-Day Moving Average | 8.67 |
| 200-Day Moving Average | 8.48 |
Over the twelve months ended September 30, 2026, Xilio Therapeutics, Inc. generated 55.01M in revenue and converted that into -11.49M in net income, yielding earnings per share of -0.80. EBITDA reached -39.87M, while operating income came in at -41.19M.
| Revenue | 55.01M |
| Operating Income | -41.19M |
| Pretax Income | -11.49M |
| Net Income | -11.49M |
| EBITDA | -39.87M |
| EBIT | -41.19M |
| Earnings Per Share (EPS) | -0.80 |
As of September 30, 2026, Xilio Therapeutics, Inc. holds 122.18M in cash and equivalents against 5.96M in total debt, resulting in a net debt position of -122.18M. Total book value stands at 68.23M, with working capital of 99.70M providing operational flexibility.
| Cash & Cash Equivalents | 122.18M |
| Total Debt | 5.96M |
| Net Debt | -122.18M |
| Equity (Book Value) | 68.23M |
| Book Value Per Share | 10.36 |
| Working Capital | 99.70M |
Xilio Therapeutics, Inc. produced -56.90M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -728,000.00 in capital expenditures, free cash flow totaled -57.62M - equivalent to -4.14 per share.
| Operating Cash Flow | -56.90M |
| Capital Expenditures | -728,000.00 |
| Free Cash Flow | -57.62M |
| FCF Per Share | -4.14 |
These figures cover the twelve months ended September 30, 2026. The operating margin of -74.87 and net profit margin of -20.89 provide insight into operational efficiency.
| Operating Margin | -74.87 |
| Pretax Margin | -20.89 |
| Profit Margin | -20.89 |
| EBITDA Margin | -72.48 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -44.14: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -127.59, meaning Xilio Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -127.59 |
| FCF Yield | -44.14 |
Xilio Therapeutics, Inc.'s most recent stock split took place on March 16, 2026 with a 14:1 split ratio.
| Last Split Date | 3/16/2026 |
| Split Ratio | 14:1 |
As of September 30, 2026, Xilio Therapeutics, Inc. has an Altman Z-Score of -3.75, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.75 |